#United States #New York #Pomerantz Law #FDA Response #Pharming Group

Pomerantz Law Firm Investigates Pharming Group N.V.

The Pomerantz Law Firm has announced an investigation concerning the Pharming Group N.V. (NASDAQ: PHAR), focusing on potential claims filed by investors. This move comes in light of recent developments involving the company's dealings and a troubling FDA response concerning one of its critical drug applications.

On February 1, 2026, Pharming disclosed that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter related to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib). This drug is intended for the treatment of children aged 4 to 11 suffering from activated phosphoinositide 3-kinase delta syndrome (APDS), a rare and serious primary immunodeficiency.

The press release indicated that the FDA had reservations regarding the dosing for lower-weight pediatric patients, raising concerns about the potential for inadequate drug exposure for these groups. This regulatory feedback necessitated Pharming to provide additional pediatric pharmacokinetic data for the FDA to reassess the proposed dosages. Additionally, the FDA pointed out issues with one of the analytical methods employed for production batch testing, again requiring further data and clarification from the company.

In response to this announcement, Pharming's stocks faced a significant downturn, with its American Depositary Receipts (ADRs) dropping by $3.495, or approximately 17.07%, closing at $16.975 per ADR the following day. Such dramatic fluctuations have understandably raised alarms among investors, prompting Pomerantz LLP to take action on their behalf.

Established by the late Abraham L. Pomerantz, esteemed as a pioneer in class action lawsuits, Pomerantz LLP has a history of championing the rights of investors. The firm has recovered extensive settlements for clients in cases of корпоративные, securities, and antitrust class litigation. With offices scattered across major global cities including New York, Chicago, and Paris, Pomerantz LLP is recognized for its commitment to fighting for victims of securities fraud and corporate mismanagement.

Investors who believe they may have been negatively affected by Pharming's recent developments are encouraged to reach out to Pomerantz LLP. Danielle Peyton, a representative of the firm, is available for direct inquiries via email or telephone. This investigation aims to evaluate whether Pharming or any of its key officers or directors engaged in misleading practices, significantly impacting investor interests.

Given the potential repercussions of this investigation, it is vital for stakeholders to stay informed and consider their legal options. As Pomerantz continues its inquiry, the outcomes, both for Pharming and its investors, remain uncertain but are undoubtedly pivotal in shaping the company’s future.

For more information regarding the investigation or to join the class action, interested parties are urged to contact Danielle Peyton at Pomerantz LLP.

This legal proceeding continues to develop, with many keeping a close eye on Pharming and the FDA’s forthcoming decisions. Stakeholders in the biotechnology sector understand the delicate balance between regulatory approvals and market performance, and this situation highlights the challenges that can arise within it.